Ovarian cancer is most common gynecological malignancy which is difficult for early diagnostics. Development of new methods for diagnostics of ovarian cancer, especially on early stage, is the urgent problem of modern oncology. A general approach to early diagnostics of cancer is a discovery of specific blood disease biomarkers. Ovarian cancer biomarker used in the modern art, CA 125, has some drawbacks resulting in extensive research recently directed to this tumor diagnosis. In particular, it was shown the advantage of parallel use of several diagnostic biomarkers instead of the single one. Proteome techniques (two-dimensional electrophoresis, mass-spectrometry methods) in connection to bioinformatics represent a powerful tool for new biomarker discovery. In this respect, the best method of choice is shown to be SELDI-TOF (Surface-enhanced laser desorption\ionization time-of-flight) technique which combines chromatography protein chip application and mass-spectrometry-based detection. In this review, new ovarian biomarker data obtained by proteome methods are summarized.
Zhou G., Li H., De Camp D., Chen S., Shu H., Gong Y., Flaig M., Gillespie J.W., Hu N., Taylor P.R., Emmert-Buck M.R., Liotta L.A., Petricoin E.F. III, Zhao Y. (2002) Mol. Cell. Proteomics, 1, 117-124. Scholar google search
Alaiva A.A., Franzen В., Moberger В., Silfversward C., Linder S., Auer G. (1999) Electrophoresis, 20, 1039-1046. Scholar google search